SAI-SUN HO: Open Payments
NPI 1710952957 · SAN FRANCISCO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,641 in 67 payments from 15 companies in 2025. Trend: 2023 $4,149 · 2024 $3,797 · 2025 $2,641
Food & beverage: $2,641
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 13 | $556 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 11 | $488 |
| Novo Nordisk Inc | 9 | $334 |
| GlaxoSmithKline, LLC. | 10 | $313 |
| Bayer Healthcare Pharmaceuticals Inc. | 8 | $234 |
| Lilly USA, LLC | 3 | $183 |
| Kowa Pharmaceuticals America, Inc. | 2 | $147 |
| PFIZER INC. | 1 | $119 |
| Gilead Sciences, Inc. | 3 | $92 |
| Sumitomo Pharma America, Inc. | 2 | $44 |
Products named: TRELEGY ELLIPTA, JARDIANCE, BREZTRI, Kerendia, FARXIGA, Ozempic, OFEV, ZORYVE.
Industry payments across CA — which companies pay providers there.
